Fate Therapeutics
FATE
159 hedge funds and large institutions have $166M invested in Fate Therapeutics in 2024 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 45 increasing their positions, 47 reducing their positions, and 40 closing their positions.
133% more call options, than puts
Call options by funds: $91K | Put options by funds: $39K
4% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 47
3% less funds holding
Funds holding: 164 → 159 (-5)
11.48% less ownership
Funds ownership: 100.77% → 89.29% (-11%)
13% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 40
59% less capital invested
Capital invested by funds: $402M → $166M (-$235M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$7.68M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.91M |
| 3 |
Walleye Capital
New York
|
+$2.56M |
| 4 |
Cerity Partners
New York
|
+$2.03M |
| 5 |
VPC
Vestal Point Capital
New York
|
+$1.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$19.5M |
| 2 |
State Street
Boston,
Massachusetts
|
-$7.62M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$5.19M |
| 4 |
D.E. Shaw & Co
New York
|
-$4.64M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$4.14M |
FATE Hedge Fund Activity: Q4 2024 in Review
159 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q4 2024, worth a combined $166M — down 59% from $402M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of FATE and 35 opened new positions — a net loss of 5 holders — while 47 trimmed existing stakes and 45 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $7.68M. The largest seller was Deep Track Capital, exiting entirely with an estimated $19.5M sold.
- 159 institutional investors held Fate Therapeutics (FATE) as of Q4 2024, down from 164 in Q3 2024.
- Funds reported $166M of Fate Therapeutics stock for Q4 2024, down 59% quarter-over-quarter.
- 35 funds opened new Fate Therapeutics positions in Q4 2024 and 40 closed out, a net change of -5 holders.
- The largest Fate Therapeutics buyer in Q4 2024 was EcoR1 Capital, an estimated $7.68M added.
- The largest Fate Therapeutics seller in Q4 2024 was Deep Track Capital, an estimated $19.5M sold.
Based on aggregated 13F filings for Q4 2024.